{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:48:16Z","timestamp":1768279696565,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81973314"],"award-info":[{"award-number":["81973314"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017668","name":"Key Research and Development Program of Anhui Province","doi-asserted-by":"crossref","award":["1804h08020291"],"award-info":[{"award-number":["1804h08020291"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lipid management is the first line of treatment for decreasing the incidence of cardiovascular events in patients with coronary heart disease (CHD), and a variety of indicators are used to evaluate lipid management. This work analyses the differences in LDL-C and apoB for lipid management evaluation, as well as explores the feasibility of skin cholesterol as a marker that can be measured non-invasively for lipid management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The prospective study enrolled 121 patients who had been diagnosed with acute coronary syndrome (ACS) at the department of emergency medicine of the First Affiliated Hospital of the USTC from May 2020 to January 2021, and the patients were grouped into Group I (<jats:italic>n<\/jats:italic>=53) and Group II (<jats:italic>n<\/jats:italic>=68) according to whether they had comorbid hyperlipidemia and\/or diabetes mellitus. All patients were administered 10\u00a0mg\/day of rosuvastatin and observed for 12 weeks. Lipid management was assessed on the basis of LDL-C and apoB, and linear correlation models were employed to assess the relationship between changes in these well accepted markers to that of changes in skin cholesterol.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 121 patients with ACS, 53 patients (43.80\u2009%) had combined hyperlipidemia and\/or diabetes mellitus (Group I), while 68 patients (56.20\u2009%) did not (Group II). Cardiovascular events occur at earlier ages in patients with CHD who are comorbid for hyperlipidemia and\/or diabetes (<jats:italic>P<\/jats:italic>&lt;0.05). LDL-C attainment rate is lower than apoB attainment rate with rosuvastatin therapy (<jats:italic>P<\/jats:italic>&lt;0.05), which is mainly attributable to patients with low initial LDL-C. Skin cholesterol reduction correlated with LDL-C reduction. (r=0.501, <jats:italic>P<\/jats:italic>&lt;0.001) and apoB reduction (r=0.538, <jats:italic>P<\/jats:italic>&lt;0.001). Skin cholesterol reduction continued over all time points measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Examination of changes in apoB levels give patients with low initial LDL-C more informative data on lipid management than LDL-C readings. In addition, non-invasive skin cholesterol measurements may have the potential to be used independently for lipid management evaluation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01571-0","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T06:37:00Z","timestamp":1634452620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements"],"prefix":"10.1186","volume":"20","author":[{"given":"Jiacheng","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshu","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meili","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"issue":"1","key":"1571_CR1","first-page":"1","volume":"33","author":"WL Chen","year":"2018","unstructured":"Chen WL, Gao RL, Liu LS, Zhu ML, Wang W, Wang YZ, et al. Summary of the China Cardiovascular Disease Report 2017. Chinese Circulation Journal. 2018;33(1):1\u20138.","journal-title":"Chinese Circulation Journal"},{"issue":"8","key":"1571_CR2","first-page":"800","volume":"321","author":"FJ Alenghat","year":"2019","unstructured":"Alenghat FJ, Davis AM. Management of Blood Cholesterol JAMA. 2019;321(8):800\u20131.","journal-title":"Management of Blood Cholesterol JAMA"},{"issue":"9438","key":"1571_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet"},{"issue":"1","key":"1571_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2013.12.016","volume":"233","author":"MR Langlois","year":"2014","unstructured":"Langlois MR, Descamps OS, van der Laarse A, Weykamp C, Baum H, Pulkki K, et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis. 2014;233(1):83\u201390.","journal-title":"Atherosclerosis"},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1571_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/HCO.0000000000000740","volume":"35","author":"A Wolska","year":"2020","unstructured":"Wolska A, Remaley AT. Measuring LDL-cholesterol: what is the best way to do it? Curr Opin Cardiol. 2020;35(4):405\u201311.","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"1571_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/clinchem\/hvab048","volume":"67","author":"M Sampson","year":"2021","unstructured":"Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clin Chem. 2021;67(7):987\u201397.","journal-title":"Clin Chem"},{"issue":"6","key":"1571_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ahj.2005.01.009","volume":"150","author":"WS Tzou","year":"2005","unstructured":"Tzou WS, Mays ME, Korcarz CE, Aeschlimann SE, Stein JH. Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults. Am Heart J. 2005;150(6):1135\u20139.","journal-title":"Am Heart J"},{"issue":"5","key":"1571_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/jocd.12428","volume":"17","author":"H Hu","year":"2018","unstructured":"Hu H, Gao Y, Tang J, Zhao Y, Wang H, Jiang H. Effect of a high-cholesterol diet on lipoprotein metabolism and xanthoma formation in rabbits. J Cosmet Dermatol. 2018;17(5):885\u20138.","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"1571_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.atherosclerosis.2005.01.017","volume":"181","author":"D Vaidya","year":"2005","unstructured":"Vaidya D, Ding J, Hill JG, Lima JAC, Crouse JR 3rd, Kronmal RA, et al. Skin tissue cholesterol assay correlates with presence of coronary calcium. Atherosclerosis. 2005;181(1):167\u201373.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1571_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2005.01.022","volume":"181","author":"DL Sprecher","year":"2005","unstructured":"Sprecher DL, Pearce GL. Elevated skin tissue cholesterol levels and myocardial infarction. Atherosclerosis. 2005;181(2):371\u20133.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1571_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ahj.2006.04.027","volume":"152","author":"DL Sprecher","year":"2006","unstructured":"Sprecher DL, Pearce GL. Skin cholesterol adds to Framingham risk assessment. Am Heart J. 2006;152(4):694\u20136.","journal-title":"Am Heart J"},{"issue":"7","key":"1571_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.amjcard.2007.11.044","volume":"101","author":"JH Stein","year":"2008","unstructured":"Stein JH, Tzou WS, DeCara JM, Hirsch AT, Mohler ER 3rd, Ouyang P, et al. Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol. 2008;101(7):986\u201391.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1571_CR14","doi-asserted-by":"publisher","first-page":"0307002","DOI":"10.3788\/CJL202148.0307002","volume":"48","author":"P Wu","year":"2021","unstructured":"Wu P, Ni J, Hong H, Li X, Yao B, Zheng H, et al. Rapid Non-Invasive Technology for Skin Cholesterol Detection Based on Fluorescent Spectrometry. Chin J Lasers. 2021;48(3):0307002.","journal-title":"Chin J Lasers"},{"issue":"1","key":"1571_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12938-021-00889-1","volume":"20","author":"J Ni","year":"2021","unstructured":"Ni J, Hong H, Zhang Y, Tang S, Han Y, Fang Z, et al. Development of a non-invasive method for skin cholesterol detection: pre-clinical assessment in atherosclerosis screening. Biomed Eng Online. 2021;20(1):52.","journal-title":"Biomed Eng Online"},{"issue":"2","key":"1571_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1253\/circj.CJ-19-0874","volume":"84","author":"W Tan","year":"2020","unstructured":"Tan W, Inoue K, AbdelWareth L, Giannitsis E, Sazzli K, Shiozaki M, et al. The Asia-Pacific Society of Cardiology (APSC) Expert Committee Consensus Recommendations for Assessment of Suspected Acute Coronary Syndrome Using High-Sensitivity Cardiac Troponin T in the Emergency Department. Circ J. 2020;84(2):136\u201343.","journal-title":"Circ J"},{"issue":"14","key":"1571_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367.","journal-title":"Eur Heart J"},{"key":"1571_CR18","doi-asserted-by":"publisher","first-page":"n1332","DOI":"10.1136\/bmj.n1332","volume":"373","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021;373:n1332.","journal-title":"BMJ"},{"issue":"2","key":"1571_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurheartj\/ehy675","volume":"40","author":"F Gragnano","year":"2019","unstructured":"Gragnano F, Calabr\u00f2 P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019;40(2):216\u20137.","journal-title":"Eur Heart J"},{"key":"1571_CR20","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139(25): e1082-e1143.","DOI":"10.1161\/CIR.0000000000000700"},{"issue":"5","key":"1571_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","volume":"5","author":"M Sampson","year":"2020","unstructured":"Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and\/or Hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540\u20138.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"1571_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen JM, Graaf JD, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337\u201345.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"1571_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287\u201395.","journal-title":"JAMA Cardiol"},{"key":"1571_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2019.12.009","volume":"294","author":"P Ohukainen","year":"2020","unstructured":"Ohukainen P, Kuusisto S, Kettunen J, Perola M, J\u00e4rvelin M, M\u00e4kinen V, et al. Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease. Atherosclerosis. 2020;294:10\u20135.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1571_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12944-020-01292-w","volume":"19","author":"L Fonseca","year":"2020","unstructured":"Fonseca L, Paredes S, Ramos H, Oliveira JC, Palma I. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol. Lipids Health Dis. 2020;19(1):127.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"1571_CR26","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s00125-019-4896-z","volume":"62","author":"H Wu","year":"2019","unstructured":"Wu H, Bragg F, Yang L, Du H, Guo Y, Jackson CA, et al. Sex differences in the association between socioeconomic status and diabetes prevalence and incidence in China: cross-sectional and prospective studies of 0.5 million adults. Diabetologia. 2019;62(8):1420\u20139.","journal-title":"Diabetologia"},{"issue":"5","key":"1571_CR27","first-page":"844","volume":"49","author":"Y Gao","year":"2020","unstructured":"Gao Y, Ping Z, Pei X, Cai Y, Wang J. [Multi-correspondence analysis of the status and related factors of chronic diseases multimorbidity in middle-aged and elderly people in China in 2009]. Wei Sheng Yan Jiu. 2020;49(5):844\u20139.","journal-title":"Wei Sheng Yan Jiu"},{"issue":"11","key":"1571_CR28","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2337\/db19-0224","volume":"68","author":"W Gan","year":"2019","unstructured":"Gan W, Bragg F, Walters RG, Millwood LY, Lin K, Chen Y, et al. Genetic Predisposition to Type 2 Diabetes and Risk of Subclinical Atherosclerosis and Cardiovascular Diseases Among 160,000 Chinese Adults. Diabetes. 2019;68(11):2155\u201364.","journal-title":"Diabetes"},{"issue":"4","key":"1571_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrcardio.2017.154","volume":"15","author":"C Andersson","year":"2018","unstructured":"Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230\u201340.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"1571_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1046\/j.0022-202x.2001.01287.x","volume":"116","author":"S Haze","year":"2001","unstructured":"Haze S, Gozu Y, Nakamura S, Kohno Y, Sawano K, Ohta H, et al. 2-Nonenal newly found in human body odor tends to increase with aging. J Invest Dermatol. 2001;116(4):520\u20134.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1571_CR31","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jocd.12474","volume":"17","author":"L Cui","year":"2018","unstructured":"Cui L, He CF, Fan LN, Jia Y. Application of lipidomics to reveal differences in facial skin surface lipids between males and females. J Cosmet Dermatol. 2018;17(6):1254\u201361.","journal-title":"J Cosmet Dermatol"},{"key":"1571_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2019.01.006","volume":"36","author":"IM Gaspar","year":"2019","unstructured":"Gaspar IM, Gaspar A. Variable expression and penetrance in Portuguese families with Familial Hypercholesterolemia with mild phenotype. Atheroscler Suppl. 2019;36:28\u201330.","journal-title":"Atheroscler Suppl"},{"issue":"3","key":"1571_CR33","doi-asserted-by":"publisher","first-page":"158592","DOI":"10.1016\/j.bbalip.2019.158592","volume":"1865","author":"CR Martins","year":"2020","unstructured":"Martins CR, Creemers E, Absalah S, Hoekstra M, Gooris GS, Bouwstra JA, et al. Hyperalphalipoproteinemic scavenger receptor BI knockout mice exhibit a disrupted epidermal lipid barrier. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(3):158592.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"2","key":"1571_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-0846.1998.tb00087.x","volume":"4","author":"AC Wright","year":"1998","unstructured":"Wright AC, Bohning DE, Pecheny AP, Spicer KM. Magnetic resonance chemical shift microimaging of aging human skin in vivo: initial findings. Skin Res Technol. 1998;4(2):55\u201362.","journal-title":"Skin Res Technol"},{"issue":"2","key":"1571_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/svn-2019-000288","volume":"5","author":"D Yang","year":"2020","unstructured":"Yang D, Ji Y, Wang D, Watase H, Hippe DS, Zhao X, et al. Comparison of carotid atherosclerotic plaques between subjects in Northern and Southern China: a Chinese atherosclerosis risk evaluation study. Stroke Vasc Neurol. 2020;5(2):138\u201345.","journal-title":"Stroke Vasc Neurol"},{"issue":"2","key":"1571_CR36","doi-asserted-by":"publisher","first-page":"104448","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104448","volume":"29","author":"Y Cao","year":"2020","unstructured":"Cao Y, Zhao X, Watase H, Hippe DS, Wu Y, Zhang H, et al. Comparison of Carotid Atherosclerosis between Patients at High Altitude and Sea Level: A Chinese Atherosclerosis Risk Evaluation Study. J Stroke Cerebrovasc Dis. 2020;29(2):104448.","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01571-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T06:40:42Z","timestamp":1634452842000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01571-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were provided with oral and written informed consent. Written informed consent was obtained from all subjects prior to enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved this manuscript and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}